TeselaGen and NinthBio Partner to Empower Users with Advanced DNA Variant Library Construction; Announcing Homology Path Design

The cutting-edge software integration enables researchers to design oligo assembly reactions, automate the reaction setup, order the needed DNA, and integrate with lab automation, all within a single platform

TeselaGen Biotechnology Inc., pioneer in AI-enabled Operating Systems for Biotechnology R&D and Manufacturing announces a strategic partnership with NinthBio LLC, the visionary Smart DNA Assembly Technology company. In a technical milestone, NinthBio’s cutting-edge Homology Path design algorithm now integrates with TeselaGen’s powerful software platform. This integration empowers researchers to accelerate their research by seamlessly enabling users to design and build DNA constructs more efficiently, saving valuable time and resources, all through a single platform.

By combining NinthBio’s Homology Path algorithm with TeselaGen’s comprehensive suite of tools, users can rapidly construct DNA variant libraries at a high throughput. The integration allows R&D teams in biotechnology to accelerate scientific discoveries and streamline their DNA assembly processes via advanced design algorithms to unlock new biotech applications enabled by protein engineering.

“By partnering with NinthBio, we empower researchers, innovators, and visionaries to unlock the full potential of biotechnology, speeding unprecedented advancements and shaping a future of limitless possibilities.”, said Eduardo Abeliuk, Ph.D., CEO of TeselaGen.

In the past, research groups outsourced the generation of their variant libraries because they lacked an efficient way to build them in-house. Now, users can seamlessly access Homology Path to quickly design oligo assembly reactions. Likewise, researchers who currently use Homology Path can lean on TeselaGen’s software to execute these reactions, including inventory management, oligo ordering, sample tracking and automated generation of worklists for liquid handling robots.

“By integrating NinthBio’s groundbreaking Homology Path design algorithm with TeselaGen’s innovative software platform, we are revolutionizing the way researchers approach DNA variant library construction,” states Steve Riedmuller, CEO of NinthBio. ”

This collaboration represents a significant step forward in advancing the field of biotechnology and reinforces both TeselaGen and NinthBio’s commitment to empowering scientists and innovators with cutting-edge tools and technologies.

“This joint effort aims to revolutionize the way DNA libraries are constructed and expedite breakthroughs in fields such as drug discovery, sustainable agriculture, and industrial biotechnology,” continues Abeliuk.

NinthBio and Teselagen will showcase their new integration at the SynBioBeta Conference, May 23-25 in Oakland, California. Conference attendees can view a demonstration of the integration and meet the team at Booth #58.

For more information about this integration or to learn more about how to build variant libraries faster and cheaper than outsourcing them, check out www.teselagen.com/integrations

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”